0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......


Basic View | Expanded View
 Showing 41-60 of 75 Articles
Original Investigation 
Kayla MD Cornett, BHK, MSc; Manoj P Menezes, MBBS, FRACP, PhD; Paula Bray, PhD; Mark Halaki, PhD; Rosemary R. Shy, MD; Sabrina W. Yum, MD; Timothy Estilow, OTR/L; Isabella Moroni, MD; Maria Foscan, PT; Emanuela Pagliano, MD; Davide Pareyson, MD; Matilde Laurá, MD, PhD; Trupti Bhandari, PT; Francesco Muntoni, MD, FRCPCH, FMed Sci; Mary M. Reilly, MD, FRCP; Richard S. Finkel, MD; Janet Sowden; Katy J. Eichinger, PT, DPT, NCS; David N. Herrmann, MBBCh; Michael E. Shy, MD; Joshua Burns, PhD; for the Inherited Neuropathies Consortium
Includes: Supplemental Content

Importance  Disease severity of childhood Charcot-Marie-Tooth disease (CMT) has not been extensively characterized, either within or between types of CMT to date.

Objective  To assess the variability of disease severity in a large cohort of children and adolescents with CMT.

Design, Setting, and Participants  A ...

Observation 
Horst Penkert, MD; Claire Delbridge, MD; Nina Wantia, MD; Benedikt Wiestler, MD; Thomas Korn, MD

This case report describes a case of fulminant central nervous system nocardiosis at 5 months after initiation of alemtuzumab in a patient with multiple sclerosis.

Editorial: Alemtuzumab and Multiple Sclerosis; Reinhard Hohlfeld, MD; Tania Kümpfel, MD

To the Editor Rosebud and colleagues1 reported on a longitudinal study strengthening the idea that olfactory impairment has potential to be a biomarker for diagnosing mild cognitive impairment (MCI) and Alzheimer disease (AD) or early detection for cognitively normal elderly individuals who would likely progress to MCI ...

Editorial 
Steven T. DeKosky, MD; Todd Golde, MD, PhD

Biomarkers as aids to diagnosis, prognosis, and effective therapies have become holy grails of translational neuroscience. In neurodegenerative disorders, especially Alzheimer disease (AD), imaging and cerebrospinal fluid (CSF) biomarkers for the amyloid-β (Aβ) protein and tau have found their place in research and clinical trials, enabling much more ...

Traumatic brain injury (TBI) is an important critical neurologic illness that requires neurocritical care. Traumatic brain injury is an active disease process in which primarily injured tissue manifests as brain hemorrhage and subsequent edema, which can lead to elevated intracranial pressure (ICP). For many years, secondary brain ischemia ...

Editorial 
Tanya Bogoslovsky, MD, PhD; Ramon Diaz-Arrastia, MD, PhD

Biomarkers are molecules that can be measured in accessible biological fluids that reflect physiological, pharmacological, or disease processes and can suggest the etiology of, susceptibility to, activity levels of, or progress of a disease. Biomarkers have historically been critical to patient progress in a broad range of clinical ...

Original Investigation 
Linda Papa, MDCM, MSc; Gretchen M. Brophy, PharmD; Robert D. Welch, MD, MS; Lawrence M. Lewis, MD; Carolina F. Braga, BA; Ciara N. Tan, BS, MHSH; Neema J. Ameli, BS; Marco A. Lopez, AS; Crystal A. Haeussler, BS; Diego I. Mendez Giordano, BS; Salvatore Silvestri, MD; Philip Giordano, MD; Kurt D. Weber, MD; Crystal Hill-Pryor, PhD; Dallas C. Hack, MD, MPH
Includes: Supplemental Content

Importance  Glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) have been widely studied and show promise for clinical usefulness in suspected traumatic brain injury (TBI) and concussion. Understanding their diagnostic accuracy over time will help translate them into clinical practice.

Objectives  To evaluate ...

Editorial: Temporal Profiles of Neuronal and Axonal Damage After Mild TBI; Tanya Bogoslovsky, MD, PhD; Ramon Diaz-Arrastia, MD, PhD
Original Investigation 
Rawan Tarawneh, MD; Gina D’Angelo, PhD; Dan Crimmins, PhD; Elizabeth Herries, BA; Terry Griest, BS; Anne M. Fagan, PhD; Gregory J. Zipfel, MD; Jack H. Ladenson, PhD; John C. Morris, MD; David M. Holtzman, MD
Includes: Supplemental Content

Importance  Synaptic loss is an early pathologic substrate of Alzheimer disease (AD). Neurogranin is a postsynaptic neuronal protein that has demonstrated utility as a cerebrospinal fluid (CSF) marker of synaptic loss in AD.

Objective  To investigate the diagnostic and prognostic utility of CSF neurogranin levels in ...

Editorial: Cerebrospinal Biomarkers in Alzheimer Disease; Steven T. DeKosky, MD; Todd Golde, MD, PhD
Original Investigation 
Tonny V. Veenith, FRCA; Eleanor L. Carter, FRCA; Thomas Geeraerts, PhD; Julia Grossac, MD; Virginia F. J. Newcombe, PhD; Joanne Outtrim, MSc; Gloria S. Gee, AS; Victoria Lupson, BSc; Rob Smith, PhD; Franklin I. Aigbirhio, PhD; Tim D. Fryer, PhD; Young T. Hong, PhD; David K. Menon, PhD; Jonathan P. Coles, PhD
Includes: Supplemental Content

Importance  Combined oxygen 15–labeled positron emission tomography (15O PET) and brain tissue oximetry have demonstrated increased oxygen diffusion gradients in hypoxic regions after traumatic brain injury (TBI). These data are consistent with microvascular ischemia and are supported by pathologic studies showing widespread microvascular collapse, perivascular ...

Clinical Pathologic Conference 
Hugo Botha, MB, ChB; Bradley F. Boeve, MD; Lyell K. Jones, MD; Joseph E. Parisi, MD; James P. Klaas, MD

A man in his late 40s presented with cognitive decline characterized by gradually increasing difficulty expressing his thoughts and ideas. His family noted word-finding difficulty, especially with the names of people, but no problems with his memory for recent events. Initial workup findings were unremarkable, but during the ...

To the Editor Fernández-Espejo and colleagues1 describe a patient with retained covert awareness who had a sharp reduction of behavioral command following.

Comment & Response 
Davinia Fernández-Espejo, PhD; Adrian M. Owen, PhD

In Reply We thank Latronico for the comments regarding our article.1 Latronico proposed that peripheral nervous system and muscle pathology2 may have contributed to the lack of behavioral responses exhibited by our patient. As mentioned in our Discussion section, Shea and Bayne3 had previously argued ...

Editorial 
Mark S. Baron, MD

In 2005, based on a review of 17 placebo-controlled trials of second-generation antipsychotics (APs) (olanzapine, aripiprazole, risperidone, and quetiapine fumarate), the US Food and Drug Administration (FDA) suggested that the use of atypical APs carries a 1.6- to 1.7-times higher incidence of mortality in elderly, demented people.1...

Editorial 
Deena M. Nasr, DO; Robert D. Brown Jr, MD, MPH

Transient ischemic attack (TIA) and stroke prediction scores have been a topic of both clinical and research interest for decades. The goal of these scores is to identify high-risk patients for both prognostic and clinical management purposes. There are several TIA and stroke prediction scores that aim to ...

Editorial 
Thomas S. Wingo, MD

The nonmotor symptoms of Parkinson disease (PD) are well recognized and are thought to often precede the overt manifestations of the motor symptoms.1 Among the cutaneous manifestations of PD, hyperhidrosis, facial flushing, and seborrheic dermatitis are well recognized, and hyperhidrosis and facial flushing are generally considered manifestations ...

Original Investigation 
Shadi Yaghi, MD; Sara K. Rostanski, MD; Amelia K. Boehme, PhD; Sheryl Martin-Schild, MD; Alyana Samai, MPH; Brian Silver, MD; Christina A. Blum, MD; Mahesh V. Jayaraman, MD; Matthew S. Siket, MD; Muhib Khan, MD; Karen L. Furie, MD, MPH; Mitchell S. V. Elkind, MD, MS; Randolph S. Marshall, MD, MS; Joshua Z. Willey, MD, MS

Importance  Neurological worsening and recurrent stroke contribute substantially to morbidity associated with transient ischemic attacks and strokes (TIA-S).

Objective  To determine predictors of early recurrent cerebrovascular events (RCVEs) among patients with TIA-S and National Institutes of Health Stroke Scale scores of 0 to 3.

Design, Setting, ...

Editorial: The Challenges of Stroke Prediction Scores; Deena M. Nasr, DO; Robert D. Brown Jr, MD, MPH
Original Investigation 
Alexander Egeberg, MD, PhD; Peter Riis Hansen, MD, PhD, DMSci; Gunnar H. Gislason, MD, PhD; Jacob P. Thyssen, MD, PhD, DMSci
Includes: Supplemental Content

Importance  The pathogenesis of rosacea is unclear, but increased matrix metalloproteinase target tissue activity appears to play an important role. Parkinson disease and other neurodegenerative disorders also display increased matrix metalloproteinase activity that contribute to neuronal loss.

Objective  To investigate the risk of incident (new-onset) Parkinson ...

Editorial: Parkinson Disease Risk in Patients With Rosacea; Thomas S. Wingo, MD
Original Investigation 
Daniel Weintraub, MD; Claire Chiang, PhD; Hyungjin Myra Kim, ScD; Jayne Wilkinson, MD, MSCE; Connie Marras, MD, PhD; Barbara Stanislawski, MPH, MSW; Eugenia Mamikonyan, MS; Helen C. Kales, MD
Includes: Supplemental Content

Importance  As many as 60% of patients with Parkinson disease (PD) experience psychosis, 80% develop dementia, and the use of antipsychotics (APs) in the population with PD is common. The use of APs by patients with dementia in the general population is associated with increased mortality, but ...

Editorial: Antipsychotics and Increased Mortality; Mark S. Baron, MD
Images in Neurology 
Naif M. Alotaibi, MD; George M. Ibrahim, MD, PhD; Hamza Jalal, MD, MSc; Bayardo Perez-Ordonez, MD; Mojgan Hodaie, MD, MSc; Suneil K. Kalia, MD, PhD

A woman in her late 50s was found to have subdural collection as an initial presentation of granulomatosis with polyangiitis.

Comment & Response 
Chan Chen, MD, PhD; Jin Liu, MD, PhD; Tao Zhu, MD, PhD

To the Editor In a prospective cohort study, De Bruijn and colleagues1 showed that atrial fibrillation (AF) “is associated with an increased risk of dementia” and the “association was strongest for younger participants with the longest duration of AF.” The study is important because it had a ...

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts